No Detail Found!

Predictors and Outcomes of Slow Flow or No Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention: A Comprehensive Analysis

Author(s)
Noor Faraz Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Qazi Najeeb Ullah Amin Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Sami Ullah Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Syed Hashim Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Abdul Basit Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Inayat Ullah Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Abstract
Objectives: This study aims to identify predictors of slow-flow or no-reflow (SF/NR) in patients undergoing primary percutaneous coronary intervention (PCI), evaluate associated clinical outcomes, and assess the effectiveness of various medications. Methodology: We conducted a prospective observational study involving 150 patients with acute coronary syndromes (ACS) treated at Hayatabad Medical Complex from July 2023 to July 2024. Data were collected on patient demographics, clinical history, laboratory tests, and procedural details. SF/NR was defined as a TIMI flow grade of <3 following PCI. We examined the incidence of SF/NR and major adverse cardiovascular events (MACE). Statistical analyses were performed using SPSS version 25.0, with multivariate logistic regression used to identify independent predictors of SF/NR. Results: SF/NR occurred in 34.7% of patients. Significant predictors identified included advanced age, male gender, diabetes mellitus, high thrombus burden, elevated high-sensitivity C-reactive protein (Hs-CRP), and reduced estimated glomerular filtration rate (eGFR). Patients presented with both single-vessel disease (SVD) and three-vessel disease (3VD). Medications used to manage SF/NR included intracoronary adenosine and epinephrine, which demonstrated variable effectiveness in improving coronary flow and reducing myocardial damage. Patients with SF/NR experienced significantly higher rates of MACE: cardiac death (10 vs. 2), recurrent myocardial infarction (8 vs. 3), target vessel revascularization (5 vs. 1), and heart failure (12 vs. 5). Multivariate analysis confirmed diabetes mellitus (OR: 1.56, CI: 1.12-2.18), high thrombus burden (OR: 2.33, CI: 1.60-3.39), and elevated Hs-CRP (OR: 1.45, CI: 1.01-2.07) as independent predictors of SF/NR. Conclusion: SF/NR represents a significant complication during primary PCI, with severe adverse outcomes. Key predictors include renal dysfunction, diabetes mellitus, and high thrombus burden. Intracoronary adenosine and epinephrine were used with varying effectiveness. Future research should focus on refining management strategies and improving patient outcomes.
Publication Details
Page(s) 337-342
Published Journal: Pakistan Heart Journal, Volume: 57, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
no-reflow, Clinical outcomes, Predictors, Slow Flow, PCI
References
Wang Y,Zhao H,Wang C,Zhang X,Tao J,Cui C .2020 .Incidence, predictors, and prognosis of coronary slow-flow and no-reflow phenomenon in patients with chronic total occlusion who underwent percutaneous coronary intervention. Ther Clin Risk Manag, 16 : 95-101.
Savic L,Mrdovic I,Asanin M,Stankovic S,Lasica R,Krljanac G .2022 .The impact of kidney function on the slow-flow/no-reflow phenomenon in patients treated with primary percutaneous coronary intervention: registry analysis. J Interv Cardiol, : 1-8.
Kai T,Oka S,Hoshino K,Watanabe K,Nakamura J,Abe M,Circ J. .2021 .Renal dysfunction as a predictor of slow-flow/no-reflow phenomenon and impaired ST segment resolution after percutaneous coronary intervention in ST-elevation myocardial infarction with initial thrombolysis in myocardial infarction grade 0. , 85 : 1770-8.
Khan MA,Samiullah JR,Shaikh JK,Butt MH,Hassan MU .2023 .Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST-Segment Resolution after Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction. A Retrospective Analysis. Pakistan J Med Heal Sci, 17 : 557-61.
Kalyoncuoglu M,Biter Hİ,Ozturk S,Belen E,Can MM .2020 .Predictive accuracy of lymphocyte-to-monocyte ratio and monocyte-tohigh-density-lipoprotein-cholesterol ratio in determining the slow flow/no-reflow phenomenon in patients with non-STelevated myocardial infarction. Coron Artery Dis, 31(6) : 518-26.
Kumar R,Khan KA,Shah JA,Ammar A,Kumar D,Khowaja S .2022 .Quantification of thrombus burden as an independent predictor of intra-procedural no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary revascularization. J Ayub Med Coll Abbottabad, 34 2 : 288-94.
Yang L,Cong H,Lu Y,Chen X,Liu Y. .2020 .Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore), 99 : E20152.
Wang Q,Shen H,Mao H,Yu F,Wang H,Zheng J .2019 .Shock index on admission is associated with coronary slow/no reflow in patients with acute myocardial infarction undergoing emergent percutaneous coronary intervention. J Interv Cardiol, : 7873468.
Ashraf T,Khan MN,Afaque SM,Aamir KF,Kumar M,Saghir T .2019 .Clinical and procedural predictors and short-term survival of the patients with no reflow phenomenon after primary percutaneous coronary intervention. Int J Cardiol, 294 : 27-31.
Kakar AW,Kumar A,Shaikh JK,Kalwar MH,Butt MH,Rizvi NH .2022 .Rate and determinants of slow flow / no-reflow in patients undergoing primary percutaneous coronary intervention at Sandaman provincial hospital Quetta. Pakistan J Med Heal Sci, 16 : 1057-61.
Hoai LT,Xuan DN,Duc HN,Tuan LN .2022 .Autologous blood injection intracoronary artery for treating slow-flow and no-reflow in acute coronary syndrome related to primary PCI. Clin Case Reports, 10(2) : e05328.
Søndergaard FT,Beske RP,Frydland M,Møller JE,Helgestad OK,Jensen LO .2023 .Soluble ST2 in plasma is associated with postprocedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care, 12(1) : 48-52.
Refaat H,Tantawy A,Gamal AS,Radwan H .2021 .Novel predictors and adverse long-term outcomes of no-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Indian Heart J, 73 : 35-43.
Savic L,Mrdovic I,Asanin M,Lasica R,Krljanac G,Rajic D .2023 .The impact of kidney function on the slow-flow/no-reflow phenomenon in patients treated with primary percutaneous coronary intervention: registry analysis. Eur Hear J Acute Cardiovasc Care, 12(Supplement) : zuad036-042.
0

Citations

0

Downloads

90

Views